1. Autophagy
  2. Autophagy

Autophagy

Autophagy is a lysosome-dependent degradative process that protects cancer cells from multiple stresses.

Autophagy, the sequestration of organelles and proteins in autophagic vesicles (AVs) and degradation of this cargo through lysosomal fusion, allows tumor cells to survive metabolic and therapeutic stresses. Therapy-induced autophagy is a key resistance mechanism to many anticancer agents, and autophagy levels are increased in most cancers. Chloroquine derivatives block autophagy by impairing lysosomal function.

Autophagy plays an emerging role in immune responses against intracellular pathogens and regulates distinct immunologic processes, important for the initiation of potent innate or adaptive immune responses.

Autophagy is important for the transport of cytoplasmic constituents such as damaged mitochondria and protein aggregates to lysosomes where they are degraded and recycled back into the cytoplasm.

Autophagy Related Products (518):

Cat. No. Product Name Effect Purity
  • HY-10162
    Olaparib Activator
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
  • HY-10181
    Dasatinib Activator
    Dasatinib is a potent and dual AblWT/Src inhibitor IC50 of 0.6 nM/0.8 nM respectively; also inhibits c-KitWT/c-KitD816V with IC50 of 79 nM/37 nM.
  • HY-10358
    MK 2206 (dihydrochloride) Activator
    MK 2206 is an orally active allosteric Akt inhibitor with IC50 of 5 nM/12 nM/65 nM for Akt1/2/3, respectively.
  • HY-10261
    Afatinib Activator
    Afatinib is an irreversible, dual EGFR/HER2 inhibitor, shows potent activity against wild-type and mutant forms of EGFR and HER2, with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-10254
    PD0325901 Activator
    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2.
  • HY-50898
    Lapatinib Activator
    Lapatinib is a potent EGFR and ErbB2 inhibitor with IC50 of 10.2 and 9.8 nM, respectively.
  • HY-10971
    Alisertib Activator
    Alisertib is a selective Aurora A inhibitor with IC50 of 1.2 nM, and is more selective for Aurora A than Aurora B.
  • HY-50878
    Crizotinib Activator
    Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-10422
    AZD-8055 Activator
    AZD-8055 is a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nM.
  • HY-12000
    AG-490 Activator
    AG-490 is an tyrosine kinase inhibitor, inhibits EGFR and Stat-3.
  • HY-50907
    ABT-737 Activator
    ABT-737 is a BH3 mimetic inhibitor of Bcl-xLBcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively, and shows no inhibition against Mcl-1, Bcl-B or Bfl-1.
  • HY-10159
    Nilotinib Activator
    Nilotinib is a second generation tyrosine kinase inhibitor (TKI), is significantly more potent against BCR-ABL than Imatinib, and is active against many Imatinib-resistant BCR-ABL mutants.
  • HY-50946
    Imatinib Mesylate Activator
    Imatinib Mesylate is a known inhibitor of the c-Kit, Bcr-Abl, and PDGFR tyrosine kinases, inhibits the SLF-dependent activation of c-Kit wt kinase with IC50 of ∼100 nM, which is similar to the concentration requires for inhibition of Bcr-Abl and PDGFR.
  • HY-10234
    Saracatinib Activator
    Saracatinib is a potent Src inhibitor with IC50 of 2.7 nM, also inhibits EGFRL861Q (IC50=4nM), EGFRL858R (IC50= 5nM) and v-Abl (IC50=30 nM).
  • HY-10130
    Veliparib dihydrochloride Activator
    Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively.
  • HY-50094
    GDC-0941 Activator
    GDC-0941 is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
  • HY-10005
    Flavopiridol Activator
    Flavopiridol is a broad inhibitor of CDK, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of around 40 nM.
  • HY-10249
    GSK-690693 Activator
    GSK-690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2/13/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. 
  • HY-10961
    CYT387 Inhibitor
    CYT387 is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.
  • HY-10161
    Tozasertib Activator
    Tozasertib is the inhibitor of Aurora-A, -B, -C kinases with Ki values of 0.6, 18, 4.6 nM, respectively.